公开(公告)号：US12162951B2

公开(公告)日：2024-12-10

申请号：US17376830

申请日：2021-07-15

Applicant: Janssen Biotech, Inc.

Inventor： Zemeda Ainekulu ,  Qiang Chen ,  Ellen Chi ,  Wilson Edwards ,  Matt Husovsky ,  Ann Lacombe ,  Quynh Nguyen ,  Paul H. Kim ,  H. Mimi Zhou ,  John T. Lee

IPC: G01N33/53 ,  C07H21/04 ,  C07K1/22 ,  C07K16/42 ,  C12N5/02 ,  C12N15/00 ,  C12P21/06 ,  G01N33/68

Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.

公开(公告)号：US12030937B2

公开(公告)日：2024-07-09

申请号：US17376874

申请日：2021-07-15

Applicant: Janssen Biotech, Inc.

Inventor： Ellen Chi ,  Wilson Edwards ,  Matt Husovsky ,  Ann Lacombe ,  Christian Martinez ,  H. Mimi Zhou ,  John T. Lee

IPC: C07K16/28 ,  G01N33/50

CPC classification number: C07K16/28 ,  G01N33/5005 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/567 ,  G01N2333/705

Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.

公开(公告)号：US20190234935A1

公开(公告)日：2019-08-01

申请号：US16341074

申请日：2017-10-11

Applicant: Janssen Biotech, Inc.

Inventor： Anthony Armstrong ,  Stephen Beck ,  Jose Antonio Chavez ,  Chen-Ni Chin ,  Thai Dinh ,  Jennifer Furman ,  Matt Husovsky ,  Xiefan Lin-Schmidt ,  Shannon Mullican ,  Shamina Rangwala ,  Vicki South

IPC: G01N33/50 ,  A61K49/00

CPC classification number: G01N33/502 ,  A61K49/0008 ,  C12Q1/6883 ,  G01N2333/495

Abstract: A novel receptor for GDF15 was identified (GFRAL), as well as the use of this receptor in the identification or screening of GDF15 agonists or antagonists. These agonist or antagonist compounds may be used to either potentiate or suppress GDF15-like effects, respectively, at the cellular and organism levels, and may be used in treatment of metabolic diseases, including obesity, type 2 diabetes, hyperglycemia, hyperinsulinemia, dyslipidemia, diabetic nephropathy, or anorexia.